Why BioNTech (BNTX) Stock Fell 3.76% in 10 Minutes on Oct 13, 2026
The 3.76% drop was larger than any reaction MoveSurge measured after BioNTech headlines between Jul 15, 2026 and Oct 12, 2026; the largest of those was +2.19% in 15 minutes, on Aug 28, 2026.
- BNTX fell 3.76% in the 10 minutes after the 06:45:19 ET headline, from $96.57 to $92.94.
- 33,733 shares changed hands in those 10 minutes.
- The headline crossed in pre-market trading, 2 hours 45 minutes before the 9:30 ET open.
06:45:19 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| BNTX | 96.57 | 96.57 | 94.33 | 92.94 | -2.32% | -3.76% |
BioNTech (BNTX) shares fell 3.76% in the 10 minutes after this headline reached the MoveSurge news feed at 06:45:19 ET on Tuesday, October 13, 2026: “Biontech SE announced that its trial will proceed to assess a second dual primary endpoint related to overall survival.”
BNTX in the first 10 minutes
From a reference price of $96.57 just before the headline, the stock was down 2.32% after one minute and down 3.76%, at $92.94, after 10 minutes. The move kept building after the first minute. 33,733 shares changed hands in those 10 minutes. The headline crossed in pre-market trading, 2 hours 45 minutes before the 9:30 ET open.
Other BNTX headlines on October 13, 2026
- 06:45 ET: “BioNTech updates on Phase 2/3 trial for mRNA cancer therapy BNT113 targeting metastatic HPV16-positive head and neck cancer.” (-3.76% in 10 minutes)
Earlier BNTX headlines and the measured reaction
The 3.76% drop was larger than any reaction MoveSurge measured after BioNTech headlines between Jul 15, 2026 and Oct 12, 2026; the largest of those was +2.19% in 15 minutes, on Aug 28, 2026.
- Aug 28, 2026, 09:15 ET: “BioNTech (BNTX) has concluded its Phase 2 clinical trial for colorectal cancer.” (+2.19% in 15 minutes)
BioNTech at a glance
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Market value | $24.36 billion (as of Oct 12, 2026) |
| Next earnings report on the calendar | Tuesday, November 3, 2026, before the open |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
What headline moved BioNTech stock on October 13, 2026?
At 06:45:19 ET, this headline crossed: “Biontech SE announced that its trial will proceed to assess a second dual primary endpoint related to overall survival.” The stock fell 3.76% in the next 10 minutes.
How far did BNTX move after the headline?
From $96.57 just before the headline to $92.94 10 minutes later, a -3.76% move.
When does BioNTech report earnings next?
The next report on the MoveSurge earnings calendar is Tuesday, November 3, 2026, before the open.
Sources
-
BNTX headline and measured reaction, Oct 13, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes recorded price reactions, search, watchlists, alerts and research tools.
Create free accountGo real time Watch live headlines -- free